Decrease of intestinal P-glycoprotein activity by 2n-propylquinoline, a new oral treatment for visceral leishmaniasis

Experimental Parasitology

Volumn 103, Issue 1-2, 2003, Pages 51-56

  Belliard, A M ^a   Leroy, C ^a   Banide, H ^a   Farinotti, R ^a   Lacour, B ^a,b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b PSL RESEARCH UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2N PROPYLQUINOLINE; ANTILEISHMANIAL AGENT; CYCLOSPORIN A; DIGOXIN; GLYCOPROTEIN P; PROTEIN INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RHODAMINE 123; UNCLASSIFIED DRUG; VERAPAMIL; 2 PROPYLQUINOLINE; 2-PROPYLQUINOLINE; ANTIPROTOZOAL AGENT; CYCLOSPORIN; DIAGNOSTIC AGENT; FLUORESCENT DYE; QUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN CELL; INTESTINE; LEISHMANIA DONOVANI; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; VISCERAL LEISHMANIASIS; ANIMAL; DRUG ANTAGONISM; DRUG RESISTANCE; ILEUM; IN VITRO STUDY; METABOLISM; SPRAGUE DAWLEY RAT;

LEISHMANIA DONOVANI; NASO HEXACANTHUS;

ANIMALS; ANTIPROTOZOAL AGENTS; CACO-2 CELLS; CYCLOSPORINE; DIGOXIN; DRUG RESISTANCE; FLUORESCENT DYES; HUMANS; ILEUM; LEISHMANIASIS, VISCERAL; MALE; P-GLYCOPROTEIN; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; RHODAMINE 123; VERAPAMIL;

EID: 0037810349     PISSN: 00144894     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-4894(03)00070-5     Document Type: Article

References (23)

1. Badaro R., Jones T.C., Carvalho E.M., Sampaio D., Reed S.G., Barral A., Teixeira R., Johnson W.D. Jr. New perspectives on a subclinical form of visceral leishmaniasis. Journal of infectious diseases. 154:1986;1003-1011.
2. Borst P., Ouellette M. New mechanisms of drug resistance in parasitic protozoa. Annual Review of Microbiology. 49:1995;427-460.
3. Fournet A., Barrios A.A., Munoz V., Hocquemiller R., Cavé A., Bruneton J. 2-Substituted quinoline alkaloids as potential antileishmanial drugs. Antimicrobial Agents and Chemotherapy. 37:1993;859-863.
4. Fournet A., Gantier J.C., Gautheret A., Leysalles L., Munos M.H., Mayrargue J., Moskowitz H., Cavé A., Hocquemiller R. The activity of 2-substituted quinoline alkaloids in BALB/c mice infected with Leishmania donovani. Journal of Antimicrobial Chemotherapy. 33:1994;537-544.
5. Fournet A., Hocquemiller R., Roblot F., Cavé A., Richomme P., Bruneton J. Les Chimanines, nouvelles quinoléines substituées en 2, isolées d'une plante bolivienne antiparasitaire: Galipea longiflora. Journal of Natural Product. 56:1993;1547-1552.
6. Grogl M., Thomason T.N., Franke E.D. Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease. American Journal of Tropical Medicine and Hygiene. 47:1992;1939-1947.
7. Henderson D.M., Sifri C.D., Rodgers M., Wirth D.F., Hendrickson N., Ullman B. Multidrug resistance in Leishmania donovani is conferred by amplification of a gene homologous to the mammalian mdr1 gene. Molecular and Cellular Biology. 12:1992;2855-2865.
8. Jackson J.E., Tally J.D., Ellis W.Y., Mebrahtu Y.B., Lawyer P.G., Were J.B., Reed S.G., Panisko D.M., Limmer B.L. Quantitative in vitro drug potency and drug susceptibility evaluation of Leishmania ssp. from patients unresponsive to pentavalent antimony therapy. American Journal of Tropical Medicine and Hygiene. 43:1990;464-480.
9. Jha T.K., Sundar S., Thakur C.P., Bachmann P., Karbwang J., Fischer C., Voss A., Berman J. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. New England Journal of Medicine. 341:1999;1795-1800.
10. Lira R., Sundar S., Makharia R., Kenney R., Gam A., Saraiva E., Sacks D. Evidence that the high incidence of treatment failures in India kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. Journal of infectious Diseases. 180:1999;564-567.
11. Neal R.A., van Bueren J., McCoy N.G., Iwobi M. Reversal of drug resistance in Trypanosoma cuzi and Leishmania donovani by verapamil. Transactions of the Royal Society of Tropical Medicine and Hygiene. 83:1989;197-198.
12. Ouellette M., Borst P. Drug resistance and P-glycoprotein gene amplification in protozoan parasite Leishmania. Research in Microbiology. 142:1991;737-746.
13. Ouellette M., Papadopoulou B. Mechanisms of drug resistance in Leishmania. Parasitology Today. 5:1993;150-153.
14. Perez-Victoria S.M., Perez-Victoria F.J., Parodi-Talice A., Jimenez I.A., Ravelo A.G., Castanys S., Gamarro F. Alkyl-lysophospholipid resistance in multidrug-resistant Leishmania tropica and chemosensitization by a novel P-glycoprotein-like transporter modulator. Antimicrobial Agents and Chemotherapy. 9:2001;2468-2474.
15. Rybczynska M., Liu R., Lu P., Sharom F.J., Steinfels E., Pietro A.D., Spitaler M., Grunicke H., Hofmann J. MDR1 causes resistance to the antitumor drug miltefosine. British Journal of Cancer. 84:2001;1405-1411.
16. Sato W., Fukazawa N., Nakanishi O., Baba M., Suzuki T., Yano O., Naito M., Tsuruo T. Reversal of multidrug resistance by a novel quinoline derivative, MS-209. Cancer Chemotherapy and Pharmacology. 35:1995;271-277.
17. Stouch T.R., Gudmundsson O. Progress in understanding the structure-activity relationships of P-glycoprotein. Advanced Drug Delivery Reviews. 54:2002;315-460.
18. Sundar S. Drug resistance in Indian visceral leishmaniasis. Tropical Medicine and International Health. 11:2001;849-854.
19. Sundar S., Singh V.P., Sharma S., Makharia M.K., Murray H.W. Response to interferon-γ plus pentavalent antimony in Indian visceral leishmaniasis. Journal of infectious diseases. 176:1997;1117-1119.
20. Suzuki T., Fukazawa N., San-nohe K., Sato W., Yano O., Tsuruo T. Structure-activity relationship of newly synthesized quinoline derivatives for reversal of multidrug resistance in cancer. Journal of Medicinal Chemistry. 40:1997;2047-2052.
21. Thankur C.P., Kanyok T.P., Pandey A.K., Sinha G.P., Messik C., Olliaro P. Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomised phase-II clinical study. Transactions of the Royal Society of Tropical Medicine and Hygiene. 94:2000;432-433.
22. WHO. 1990. The control of leishmaniases: report of an expert committee. World Health Organization Technical Report Series 701, 99-108.
23. WHO, 2000. The Leishmaniasis and Leishmania/HIV co-infections. World Health Organization Fact Sheet 116.